DRUG
Bright Minds
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
DRUG Profile
Bright Minds Biosciences Inc.
A biotech company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain
Biological Technology
05/31/2019
11/08/2021
NASDAQ Stock Exchange
0
09-30
Common stock
19 Vestry Street, New York, NY 10013
--
Bright Minds Biosciences Inc., was incorporated on May 31, 2019 under the British Columbia Business Companies Act. The company is a biotechnology company that develops treatments to improve the lives of patients with serious diseases. The company is creating new chemical entities as targeted therapeutic agents for the treatment of diseases with underlying pathologies driven by serotonin (5-HT) receptor (5-HT2A, 5-HT2C or 5-HT2A/C) mechanisms.